Related Experiment Video

Updated: May 10, 2026

Electrochemiluminescence Assays for Human Islet Autoantibodies
09:15

Electrochemiluminescence Assays for Human Islet Autoantibodies

Published on: March 23, 2018

Serum dipeptidyl peptidase 4 activity in children with type 1 diabetes mellitus

Atsushi Iwabuchi, Tomohiro Kamoda, Makoto Saito

    Journal of Pediatric Endocrinology & Metabolism : JPEM
    |July 3, 2013
    PubMed

    Insights

    Serum dipeptidyl peptidase 4 (DPP4) activity is elevated in children with type 1 diabetes mellitus (T1DM) but does not correlate with glycemic control. However, it shows a negative association with adiponectin levels in T1DM patients.

    Area of Science:

    • Endocrinology
    • Metabolic Research
    • Pediatric Diabetes

    Background:

    • Dipeptidyl peptidase 4 (DPP4) role in glycemic control is unclear in type 1 diabetes mellitus (T1DM).
    • Understanding DPP4's contribution to metabolic alterations in T1DM is crucial.

    Purpose of the Study:

    • To quantify serum DPP4 activity in children with T1DM.
    • To investigate the relationship between serum DPP4 activity and metabolic variables in pediatric T1DM.

    Main Methods:

    • Fluorometric assay used to measure serum DPP4 activity.
    • Study included 43 children with T1DM and 26 healthy controls.

    Main Results:

    • Serum DPP4 activity was significantly higher in T1DM children compared to controls.
    • DPP4 activity did not correlate with HbA1c, blood glucose, or diabetes duration in T1DM.
    • A negative correlation was observed between DPP4 activity and serum adiponectin levels in T1DM children.

    Conclusions:

    • Elevated serum DPP4 activity in T1DM children is not linked to glycemic control.
    • Further research is needed to explore DPP4's impact on insulin sensitivity in T1DM, considering its association with adiponectin.
    Abstract

    More Related Videos

    High Resolution 3D Imaging of the Human Pancreas Neuro-insular Network09:54

    High Resolution 3D Imaging of the Human Pancreas Neuro-insular Network

    Published on: January 29, 2018

    Measurement of Differentially Methylated INS DNA Species in Human Serum Samples as a Biomarker of Islet β Cell Death10:34

    Measurement of Differentially Methylated INS DNA Species in Human Serum Samples as a Biomarker of Islet β Cell Death

    Published on: December 21, 2016

    Related Concept Videos

    Dipeptidyl Peptidase 4 Inhibitors01:23

    Dipeptidyl Peptidase 4 Inhibitors

    Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...
    Type I Diabetes III: Clinical Manifestations01:19

    Type I Diabetes III: Clinical Manifestations

    Type 1 diabetes mellitus typically presents with rapid-onset symptoms due to the body’s inability to utilize glucose in the absence of insulin. Since insulin is required for glucose uptake into cells, its deficiency leads to hyperglycemia and cellular energy deprivation, resulting in characteristic clinical features.Polyuria and PolydipsiaOne of the earliest, most prominent symptoms is polyuria (excessive urination). When blood glucose concentrations rise above the renal threshold, the kidneys...
    Diabetes Mellitus: Overview and Type I Subtype01:22

    Diabetes Mellitus: Overview and Type I Subtype

    Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
    Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
    Insulin: Dosing Regimen and Adverse Effects01:16

    Insulin: Dosing Regimen and Adverse Effects

    Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
    The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
    Type I Diabetes I: Introduction01:12

    Type I Diabetes I: Introduction

    Type 1 diabetes mellitus is a chronic metabolic disorder characterized by an absolute deficiency of insulin resulting from the autoimmune destruction of pancreatic β-cells. Although it can occur at any age, it is most commonly diagnosed in childhood, adolescence, or early adulthood. The loss of insulin production impairs cellular glucose uptake, resulting in persistent hyperglycemia and necessitating lifelong insulin therapy.Autoimmune Destruction of β-CellsThe hallmark of type 1 diabetes is an...
    Diabetes Mellitus: Type 2 and Gestational01:22

    Diabetes Mellitus: Type 2 and Gestational

    Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...